The effect of corticosteroid usage on the bacterial killing, clearance and nerve damage in leprosy: A prospective cohort study: Part 1 - Study design and baseline findings of 400 untreated multibacillary patients

Leprosy Review

Volumn 79, Issue 2, 2008, Pages 134-153

  Khambati, Fatema Abbas ^a   Shetty, Vanaja Prabhakar ^a   Ghate, Sunil Dattatraya ^a   Capadia, Gospi Dolly ^a   Pai, Vivek Vasudev ^b   Ganapati, Ramaswamy ^b  

^a FOUNDATION FOR MEDICAL RESEARCH   (India)

^b Bombay Leprosy Project   (India)

Author keywords

[No Author keywords available]

Indexed keywords

LEPROSTATIC AGENT; PREDNISOLONE;

ADOLESCENT; ADULT; ARTHRITIS; ARTICLE; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; BORDERLINE LEPROSY; CLINICAL EXAMINATION; CONTROLLED STUDY; DISABILITY; DISABILITY SEVERITY; DRUG DOSE REDUCTION; EDEMA; ERYTHEMA; FEMALE; FEVER; FUNCTIONAL DISEASE; GRANULOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IRITIS; LEPROMATOUS LEPROSY; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MULTIBACILLARY LEPROSY; MYCOBACTERIUM LEPRAE; NERVE CONDUCTION; NERVE FUNCTION; NERVE INJURY; NEURITIS; NEUROLOGIC EXAMINATION; NEUROPATHY; ORCHITIS; SCHOOL CHILD; SKIN DEFECT; TUBERCULOID LEPROSY; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; COHORT STUDIES; FEMALE; HUMANS; LEPROSTATIC AGENTS; LEPROSY; MALE; MIDDLE AGED; NEURAL CONDUCTION; NEUROLOGIC EXAMINATION; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 51349087657     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Naafs B. Treatment of reactions and nerve damage. Int J Lepr, 1996; 64: S21-S28.
2. Britton WJ. The management of leprosy reversal reactions. Lepr Rev, 1981; 69: 225-234.
3. Lockwood DNJ. Steroids in leprosy type 1 (reversal) reactions: mechanisms of action and effectiveness. Lepr Rev, 2000; 71: S111-S114.
4. Scollard M, Smith T, Bhoopat L et al. Epidemiologic characteristics of leprosy reaction. Int J Lepr, 1994; 62: 559-567.
5. WHO. A guide to elimination of leprosy as public health problem, 2nd edn., WHO/CDS/LEP/97.7, Geneva, 1987;.
6. Pannikar V, Jasudasa K, Vijaykumaran P, Christia M. Relapse or late reversal reaction. Int J Lepr, 1989; 57: 526-528.
7. Lienhardt C, Fine PEM. Type 1 reaction, neuritis and disability in leprosy. What is the current epidemiological situation? Lepr Rev, 1994; 65: 9-33.
8. Van Den Akker THW, Naafs B, Kolk AHJ et al. Similarity between mycobacterial and human epidermal antigens. Br J Dermatol, 1992; 127: 352-358.
9. Srinivasan H, Rao KS, Shanmugam N. Steroid therapy in recent "quiet nerve paralysis" in leprosy. Report of a study of twenty-five patients. Lepr India, 1982; 54: 412-419.
10. Kiran KU, Stanley JN, Pearson JM. The outpatient treatment of nerve damage in patients with borderline leprosy using a semi-standardised steroid regimen. Lepr Rev, 1985; 56: 127-134.
11. Sugamaran DST. Steroid therapy for paralytic deformities in leprosy. Int J Lepr, 1997; 67: 337-344.
12. Sundar Rao PSS, Sugamaran DST, Richard J, Smith WCS. Multi-centric, double blind, randomised trial of three steroid regimens in the treatment of type 1 reactions in leprosy. Lepr Rev, 2006; 77: 25-33.
13. Smith WCS, Anderson AM, Withington SG et al. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). BMJ, 2004; 328: 1459.
14. Naafs B. Treatment duration of reversal reaction: a re-appraisal. Back to the past. Lepr Rev, 2003; 74: 328-336.
15. Richardus JH, Withington SG, Anderson AM et al. Adverse events of standardised regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy; results from the TRIPOD trial. Lepr Rev, 2003; 74: 319-327.
16. Kumar B, Dogra S, Inderjeet K. Epidemiological characteristics of leprosy reactions: 15 years experience from North India. Int J Lepr, 2004; 72: 125-133.
17. Jamet P, Ji B, Marchoux chemotherapy study group. Relapse after long term follow up of multibacillary patient treated by WHO multidrug regimen. Int J Lepr, 1995; 63: 195-201.
18. Waters MRF. Relapse following various types of multidrug therapy in multibacillary leprosy (Editorial). Lepr Rev, 1995; 66: 1-9.
19. Girdhar BK, Girdhar A, Kumar A. Relapses in multibacillary leprosy patient: effect of length at therapy. Lepr Rev, 2000; 71: 144-153.
20. Ji B. Does there exist a subgroup of MB patients at greater risk of relapse after MDT? (Editorial). Lepr Rev, 2001; 72: 3-7.
21. Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J Clin Microbiol Dis, 1994; 13: 908-914.
22. Pattyn S, Grillone S. A 6 week quadruple drug regimen for the treatment of multibacillary leprosy. Lepr Rev, 2000; 71: 43-46.
23. Shetty VP, Uplekar MW, Antia NH. Immunohistological localisation of mycobacterial antigens within the peripheral nerves of treated leprosy patients and their significance to nerve damage in leprosy. Acta Neuropathol, 1994; 88: 300-306.
24. Shetty VP, Suchitra K, Uplekar MW, Antia NH. Higher incidence of viable M. leprae within the nerve as compared to skin among multibacillary leprosy patients released from multi drug therapy. Lepr Rev, 1997; 68: 111-138.
25. WHO expert committee on leprosy. WHO technical report series, 1998; 874.
26. WHO expert committee on leprosy. WHO technical report series, 1988; 768: 1-51.
27. Ridley DS. The bacteriological interpretation of skin smears and biopsies in leprosy. Trans R Soc Trop Med Hyg, 1955; 49: 449-452.
28. Bell-Krotoski JA. Pocket filaments and specifications for the Semmes-Weinstein monofilaments. J Hand Ther, 1990; 3: 26-31.
29. Anderson AM, van Brakel WH. Age specific normal thresholds for sensibility testing with monofilaments in a Nepali population. Int J Lepr, 1998; 66: 69A.
30. Bradsma JW. Monitoring motor nerves function in leprosy patients. Lepr Rev, 2000; 71: 258-267.
31. DeLisa JA, Hang JL, Baran EM et al. Temperature effects on nerve conduction velocities and latencies, manual of nerve conduction velocity and clinical neurophysiology Raven, New York, 1994; pp. 1-21.
32. Wheeler E, Hamilton E, Harman D. An improved technique for the histopathological diagnosis and classification of leprosy. Lepr Rev, 1965; 36: 37-39.
33. Sternberger LA, Hardy PH, Cuculis JJ, Mayer HG. The unlabelled antibody enzyme method of immunohistochemistry. Preparation and properties of soluble antigen-antibody complex (horseradish peroxidase antihorse radish peroxidase) and its use in the identification of Spirocheates. J Histochem Cytochem, 1970; 18: 315-333.
34. WHO. Laboratory techniques for leprosy, World Health Organization, CDS/LEP 86.4, Geneva, 1987.
35. Shepard CC. The experimental disease that follows the injection of human leprosy bacilli into foot pads of mice. J Exp Med, 1960; 112: 445-454.
36. Ridley DS, Jopling WH. Classification of leprosy according to immunity - a five group system. Int J Lepr, 1966; 34: 255-273.
37. Pimentel MIF, Nery JAC, Borges E et al. Impairments in multibacillary leprosy; a study from Brazil. Lepr Rev, 2004; 75: 143-152.
38. Van Brakel WH, Nicholls PG, Das L et al. The INFIR cohort study: assessment of sensory and motor neuropathy in leprosy at baseline. Lepr Rev, 2005; 76: 277-295.
39. Lobo D, Narain JP. Progress of leprosy elimination in the South-East Asia region. Reg Health Forum, 2005; 9: 21-27.
40. Kumar A, Girdhar A, Girdhar BK. Nerve thickening in leprosy patients and risk of paralytic deformities: a field based study in Agra, India. Lepr Rev, 2004; 75: 135-142.
41. Brown TR, Kovindha A, Wathanadilokkol U et al. Leprosy neuropathy: correlation of clinical and electrophysiological tests. Indian J Lepr, 1996; 68: 1-15.
42. Mittal A, Masuria BL, Gupta LK et al. Thickening of peripheral nerves in neurofibromatosis. Indian J Dermatol Venereol Leprol, 1997; 63: 63-64.
43. Jopling WH. Differential diagnosis. In: Jopling WH, McDougall AC (eds). Handbook of leprosy, CBS Publisher, Delhi, 1992, pp. 151-152.
44. Masayuki B. Chronic inflammatory demyelinating polyneuropathy: treatable hypertrophic neuropathy. Intern Med, 1999, 38: 384-385.
45. Kolappan C, Selvaraj R, Khudoos A et al. Repeatability of nerve thickness assessment in the clinical examination for leprosy. Lepr Rev, 1995; 66: 224-228.
46. Donde SV, Shah A, Antia NH. Nerve conduction in leprosy: in vivo and in vitro study. Lepr India, 1983; 55: 12-21.
47. Antia NH, Shetty VP, Mehta LN. Study of evolution of nerve damage in leprosy. Lepr India, 1980; 52: 48.
48. Samant G, Shetty VP, Uplekar MW, Antia NH. Clinical and electrophysiological evaluation of nerve function impairment following cessation of multidrug therapy in leprosy. Lepr Rev, 1999; 70: 10-20.
49. Sabin TD, Swift TR. Leprosy. In: Dyck PJ, Thomas PK, Lambert EH, Bunge R (eds). Peripheral neuropathy, 2nd edn. Saunders, Philadelphia, PA, 1984, pp. 1955-1987.
50. Karat S, Karat ABA, Pitchandy P. Electromyographic findings in conduction velocities of the ulnar nerve in leprosy. Lepr India, 1970; 42: 77-84.
51. Singh T, Kaur S, Kumar B. A study of motor and sensory nerve conduction in leprosy. Indian J Med Res, 1977; 65: 632-639.
52. Kaplan M, Gelber RH. Evaluation of testing modalities for peripheral neuropathy in lepromatous Hansen's disease. Phys Ther, 1985; 65: 1662-1665.
53. Gilbody JS. Aspects of rehabilitation in leprosy. Int J Lepr, 1992; 60: 608-640.
54. Smith WCS, Nicholls PG, Richardus JH, Croft RP. Motor impairment without sensory impairment in leprosy. Int J Lepr, 1998; 66: 82A.
55. Van Brakel WH, Nicholls PG, Das L, Barkataki P. The INFIR cohort study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in North India. Lepr Rev, 2005; 76: 14-34.